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Efficient homing of antibody-secreting cells to the
bone marrow requires RNA-binding protein ZFP36L1
Alexander Saveliev, Sarah E. Bell, and Martin Turner
Cell migration relies on coordinated activity of chemotactic and guidance receptors. Here, we report a specific role for the
RNA-binding protein ZFP36L1 in limiting the abundance of molecules involved in the homing of antibody-secreting cells (ASCs)
to the bone marrow (BM). In the absence of ZFP36L1, ASCs build up in the spleen and the liver and show diminished
accumulation in the BM. ZFP36L1 facilitates migration by directly regulating G protein–coupled receptor kinase 2 (GRK2) and
the integrin chains α4 and β1 in splenic ASCs. Expression of CXCR4 and of the integrins α4 and β1 is differentially regulated on
ASCs produced at the early and late stages of the immune response. Consequently, deletion of the Zfp36l1 gene has a
stronger effect on BM accumulation of high-affinity ASCs formed late in the response. Thus, ZFP36L1 is an integral part of the
regulatory network controlling gene expression during ASC homing.
Introduction
Long-term humoral immunity is derived from the generation
and persistence of memory B cells and antibody-secreting cells
(ASCs) following infection. It is generally accepted that long-
lived ASCs are formed in secondary lymphoid organs from
B cells after they undergo affinity maturation of Igs in germinal
centers (GCs; Victora and Nussenzweig, 2012; Suan et al., 2017;
Nutt et al., 2015; Shlomchik and Weisel, 2012). Newly generated
ASCs then migrate to the bone marrow (BM), where ASC sur-
vival and function are sustained for extended periods of time
(Slifka et al., 1998; Manz et al., 1997). Understanding the mech-
anisms regulating ASC homing is thus important for improving
vaccine efficacy and immunity.
Egress of ASCs from the spleen depends on the action of the
chemokine CXCL12 and its receptor CXCR4, as well as sphin-
gosine-1-phosphate (S1P) and its receptor S1PR1 (Hargreaves
et al., 2001; Kabashima et al., 2006; Lu and Cyster, 2019). Once
in the blood, ASC homing to the BM is guided primarily by the
CXCL12/CXCR4 pair (Hauser et al., 2002; Bowman et al., 2002;
Luther et al., 2002). The integrin dimer α4β1 activated by CXCR4
signaling mediates rolling, firm adhesion, and arrest on the
fenestrated endothelium lining BM sinusoids (Chan et al., 2001;
Peled et al., 2000; Grabovsky et al., 2000). Recently, it was
shown that reduced activation of the integrin β1 on early ASCs in
mice deficient for the cochaperone Mzb1 was associated with
their impaired trafficking to the BM (Andreani et al., 2018).
While another integrin dimer, α4β7, is mainly thought of as an
adhesion molecule directing migration of lymphocytes to the
intestine, antibody-blocking and genetic experiments also suggest
a role for this integrin in BM homing (Katayama et al., 2004;
Murakami et al., 2016).
It is known that the adhesive properties of integrins must be
precisely regulated (Bouvard et al., 2013) and that excessive
surface abundance of integrins, or their abnormal activation,
can inhibit rather than promote chemokine-induced migration
(Imai et al., 2008; Lu and Cyster, 2002). In this way, the de-
fective accumulation of ASCs lacking the tyrosine phosphatase
SHP1 (encoded by Ptpn6) in the BM of mice has been linked to
aberrant activation of the integrin α4β1 (Li et al., 2014), while
impaired de-adhesion of α4β7 has been reported to affect mi-
gration of lymphocytes to the gut (Park et al., 2007). Dynamic
modulation of S1PR1 and CXCR4 activity is also known to be
critical for themigration and survival of ASCs (Arnon et al., 2011;
Biajoux et al., 2016). While signaling pathways mediate acute
responses to adhesive and chemotactic cues, transcription
factor–mediated control of mRNA abundance is thought to be
the principal mechanism by which ASCs reprogram their ad-
hesive and chemotactic properties.
Transcription factors such as BLIMP1, c-Myb, and KLF2
couple differentiation to adhesion and migration (Minnich et al.,
2016; Winkelmann et al., 2011; Good-Jacobson et al., 2015).
However, the rapid and transient repression of gene expression
or the localized translation that would enable complex cell be-
havior is not well suited to transcriptional regulation. Hence,
posttranscriptional control of gene expression is increasingly
recognized as having an essential contribution to the differen-
tiation, migration, and longevity of ASCs (Corcoran and Tarlinton,
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2016; Khodadadi et al., 2019). MicroRNA-mediated regulation
appears to be a common feature of these processes (Porstner
et al., 2015; Lu et al., 2014; Vigorito et al., 2007; Basso et al., 2012).
In particular, mir-17-92 has been shown to directly control ASC
homing to the BM by targeting the 39 untranslated region (39
UTR) of S1PR1 mRNA (Xu et al., 2015). In contrast, roles for RNA-
binding proteins in ASC trafficking and survival have yet to be
identified.
ZFP36L1 is a member of the ZFP36 family of RNA-binding
proteins that can interact with AU-rich elements in the 39UTR of
mRNA and attenuate expression of the corresponding genes
(Brooks and Blackshear, 2013). In lymphocytes, it has been
shown to play redundant roles with its paralogue ZFP36L2 in
developing T and B cells (Hodson et al., 2010; Galloway et al.,
2016; Vogel et al., 2016). More recently, ZFP36L1 was demon-
strated to have an indispensable function in maintaining the
population of marginal zone (MZ) B cells (Newman et al., 2017).
The roles of ZFP36L1 in the GC response and immunological
memory are unknown. Here, we report a specific requirement
for ZFP36L1 in the BM homing of ASCs. By limiting the ex-
pression of key molecules mediating migration, ZFP36L1 facili-
tates unimpeded transition of ASCs from secondary lymphoid
organs to their survival niche in the BM, thereby promoting the
establishment of long-term ASCs.
Results
ZFP36L1 in B cells determines the numbers of BM ASCs
To identify a role for ZFP36L1 in B cells during humoral immune
responses, we used mice with B cell–specific deletion of a con-
ditional Zfp36l1 allele (Zfp36l1fl; Newman et al., 2017). At 14 and
21 d following immunization with alum-precipitated 4-hydroxy-
5-nitrophenylacetyl (NP) conjugated to KLH, Zfp36l1fl/fl CD79a+/+
(control) and Zfp36l1fl/fl CD79aCre/+ (Zfp36l1 conditional KO
[Zfp36l1 cKO]) mice had similar numbers of NP-binding IgG1+
GC B cells in the spleen (Fig. S1, A and B). The affinity matura-
tion of NP-reactive IgG1 antibody, as determined by the ratio of
serum antibody with high affinity to antibody with all affinities,
was evident early in the immune response and indistinguishable
between Zfp36l1 cKO and control mice (Fig. S1 C). Furthermore,
the number of NP-2–binding (high affinity) IgG1-secreting ASCs,
as enumerated by ELISPOT, was slightly increased in the spleens
of the Zfp36l1fl/fl CD79aCre/+ mice compared with that of Zfp36l1fl/fl
CD79a+/+ mice (Fig. 1 A). This was also true for ASCs secreting
NP-reactive antibody irrespective of affinity (Fig. S1 D). Thus,
the GC response in the spleen shows no impairment when
ZFP36L1 is absent from B cells. Despite this, the frequency of NP-
specific ASCs in the BM of Zfp36l1fl/fl CD79aCre/+ mice did not
reach the level observed in Zfp36l1fl/fl CD79a+/+ mice (Fig. 1, B and
C), resulting in a modest decrease of NP-specific antibody in
serum (Fig. S1, E and F). Failure by serum antibody titers to
closely follow the reduction in the ASC numbers is not un-
precedented (Takahashi et al., 1998; Holl et al., 2011) and prob-
ably reflects the high productivity of ASCs (Hibi and Dosch,
1986; Taubenheim et al., 2012) and variability in Ig production
by individual cells. In summary, while the initial stages of ASC
differentiation in the spleen take place independently of ZFP36L1,
it is required for their accumulation in the BM. This could reflect a
role for ZFP36L1 in the migration of ASCs to the BM and in their
subsequent survival.
The protracted nature of a primary immune response, the
paucity of ASCs generated, and the diminished expression of
surface Ig upon ASC maturation prevents easy identification
and tracking of newly formed antigen-specific ASCs. There-
fore, to address questions about the role of ZFP36L1 in ASCs,
we set up a system that allowed us to follow a synchronized
wave of NP-specific ASCs. We reimmunized mice with NP-KLH
in alum 21 d after primary immunization and used intracellular
staining for IgG1 antibody recognizing 4-hydroxy-3-iodo-5-
nitrophenylacetic acid (NIP) to identify elicited ASCs among
all eFluor780−IgD−CD4−CD8−CD138+CD267+ cells (Fig. 1 D).
The absence of NIPhiIgG1hi cells (subsequently referred to as
CD138+NIP+IgG1+ cells) in nonimmunized mice confirmed the
specificity of staining (Fig. 1 D, rightmost plots), while their low
frequency (8–9% at day 5 after reimmunization) among all
CD138+CD267+ cells (Fig. 1 D, middle plots) underscored the lim-
itations of analyzing the whole CD138+CD267+ population when
following the fate of elicited ASCs. Enumeration of CD138+NIP+IgG1+
cells in the spleen and BM of Zfp36l1fl/fl CD79aCre/+ and Zfp36l1fl/fl
CD79a+/+ mice after reimmunization (Fig. 1, E and F) reca-
pitulated the phenotype observed in the primary response.
The consistency of observations in both settings indicates that
reimmunization can be useful for understanding specific defects
in ZFP36L1-deficient ASCs.
ZFP36L1 controls migration of newly formed ASCs to the BM
To discriminate between the outcomes of ASCs homing to the
BM and of their subsequent survival, we monitored the ap-
pearance of NP-specific ASCs in the BM by giving mice BrdU in
their drinking water the day after reimmunization and for the
duration of the secondary response (Fig. 2 A). Incorporation of
BrdU into the DNA of proliferating cells allows the identification
of a population of antigen-specific ASCs elicited by the second-
ary immunization, which can be followed by flow cytometry.
Consequently, staining of BM CD138+NIP+IgG1+ cells with anti-
BrdU antibody revealed two distinct populations of ASCs: the
BrdU-low population of quiescent ASCs established before day
22 and the BrdU-high ASCs that emerged after secondary im-
munization (Fig. 2 B). Interestingly, BrdU-low CD138+NIP+IgG1+
cells stained more strongly for NIP than BrdU-high cells, likely
reflecting the increased production of antibody by ASCs estab-
lished in the BM. This aspect of ASC maturation was not dif-
ferent between Zfp36l1fl/fl CD79aCre/+ and Zfp36l1fl/fl CD79a+/+ mice
(Fig. S2, A and B).
Tracing the BrdU-high CD138+NIP+IgG1+ cells in control mice
over the course of the secondary response showed that in this
system the newly generated ASCs do not appear in the BM until
day 4 after reimmunization (Fig. S2, C and D). Analysis at this
time point demonstrated an accumulation of the newly gener-
ated CD138+NIP+IgG1+ cells in the spleens of Zfp36l1 cKO mice
(Fig. 2, C and D). The numbers of CD138+NIP+IgG1+ cells that
migrated to the BM of Zfp36l1 cKO mice before and after day
24 (the last day before the appearance of elicited ASCs in the
BM) were lower (Fig. 2, E–G), in agreement with previous
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observations (Fig. 1, B, C, and F). The difference in accumulation
of ZFP36L1-sufficient and ZFP36L1-deficient ASCs in both the
spleen and the BM was observed irrespective of whether the
CD79aCre or Cd23-Cre allele was used to delete the Zfp36l1 gene
(Fig. 2, C–G). Taken together, these data suggest that the re-
duction in ASC numbers in the BM results from the defective
egress of ZFP36L1-deficient ASCs from the spleen.
4 d after secondary immunization, the population of the BM
BrdU-low CD138+NIP+IgG1+ cells combined all NP-specific ASCs
that were successful in migrating, differentiating, and surviving
in the BM during the previous 24 d of the immune response,
while the BrdU-high CD138+NIP+IgG1+ cells were the cells that
migrated to the BM in the 24-h period before the analysis.
Therefore, the ratio of BrdU-low to BrdU-high CD138+NIP+IgG1+
cells in the BM relates the number of established ASCs to the
number of newly generated ASCs that arrived in the BM in a
defined period of time immediately before the analysis. As this
ratio is the same in Zfp36l1 cKO and control mice (Fig. 2 H), the
observed reduction in the numbers of NP-specific ASCs in the
BM can be fully explained by a failure of ZFP36L1-deficient ASCs
to find their way to the BM.
ZFP36L1-deficient ASCs have defective responses to S1P
The migration of ASCs from secondary lymphoid organs to their
long-term survival niches in the BM has been extensively
studied. In the spleen, ASCs initially accumulate in a CXCR4-
dependent manner near the sinusoids in the red pulp (Hargreaves
et al., 2001). Their entry into the bloodstream has been shown
to depend on S1PR1 (Kabashima et al., 2006). To assess the
effects of ZFP36L1 deletion on the migratory capacity of ASCs,
we used a transwell migration assay. Only 0.5–1% of the input
ASCs are able tomigrate toward S1P in these settings (Kabashima
Figure 1. Accumulation of Ag-specific ASCs in the BM but not their generation in the spleen is impaired after both primary immunization and
reimmunization in Zfp36l1fl/fl CD79aCre/+ mice. (A–C) ELISPOT analysis of NP-specific ASCs in Zfp36l1fl/fl CD79a+/+ (closed circles) and Zfp36l1fl/fl CD79aCre/+
(open squares) mice. Enumeration of ASCs secreting anti-NP2 (high affinity) IgG1 antibody in the spleen (A) and BM (B) and of ASCs secreting anti-NP23 (high and low
affinity) IgG1 antibody in the BM (C). For all plots in all panels, each symbol displays data from an individual mouse, lines represent means, and data are representative of
two independent experiments for day 14 (n ≥ 4; two-way ANOVA on logarithmically transformed data; the P values shown are for the main genotype effect).
(D) Representative flow cytometry plots showing intracellular staining with IgG1 antibody and NIP-BSA-biotin to identify NP-specific ASCs in the spleen (three top plots)
and the BM (three bottom plots); intracellular NIPhi, IgG1hi cells (middle plots) were identified in the population of all CD138+CD267+ cells (left plots, gated on
eFluor780−CD3−IgD− cells), and their absence was confirmed in a nonimmunized mouse (right plots). (E and F) Quantification of CD138+NIP+IgG1+ cells in Zfp36l1fl/fl
CD79a+/+ (closed circles) and Zfp36l1fl/fl CD79aCre/+ (open squares) mice at days 5 and 6 after reimmunization in the spleen (E) and the BM (F) normalized to the numbers of
all eFluor780− cells in the sample (n ≥ 4; two-way ANOVA; the P values shown are for the main genotype effect). For all flow cytometry plots, the numbers next to the
enclosed areas (gates) represent percentages of the cells falling into the gate, and the number in the bottom right corner shows the number of cells in the plot.
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et al., 2006), making measurements of ex vivo antigen-specific
ASC migration very challenging. Therefore, we used ASCs gen-
erated in vitro by activating follicular B (FoB) cells from the LNs
of Zfp36l1fl/fl CD79a+/+ and Zfp36l1fl/fl CD79aCre/+ mice with LPS for
96 h. Control ASCs showed a low but consistent migration that
was enhanced by increasing the concentration of S1P. However,
the ability of ZFP36L1-deficient ASCs to migrate to S1P was only
slightly above the background level, and the cells were unre-
sponsive to increased concentrations of S1P (Fig. 3 A). Notably,
ZFP36L1-sufficient and ZFP36L1-deficient ASCs were equally
efficient inmigrating toward the CXCR4 ligand CXCL12 (Fig. 3 B).
This observation demonstrated that the lack of response to S1P
was specific rather than a reflection of a general failure to re-
spond to a chemotactic cue.
Examination of splenic sections from Zfp36l1fl/fl CD79a+/+ and
Zfp36l1fl/fl CD79aCre/+ mice taken 4 d after reimmunization, when
an accumulation of CD138+NIP+IgG1+ ASCs can be clearly de-
tected by flow cytometry (Fig. 2 C), revealed cells with very high
cytoplasmic staining for NIP and IgG1 that were consistently
found in clusters in the red pulp in the mice of either genotype
(Fig. S2, E and F), as would be expected for ASCs lacking the
capacity to migrate to S1P (Kabashima et al., 2006). Consistent
with intact CXCR4 responsiveness, we did not detect any ab-
normal accumulation of NIPhiIgG1hi cells within the follicle or
adjacent to the MZ, as was described for CXCR4-deficient ASCs
(Hargreaves et al., 2001). A similarly unaltered localization of
NIPhiIgG1hi cells was observed in mice analyzed 14 d after pri-
mary immunization (data not shown). Overall, these results
Figure 2. Reduced number of Ag-specific ASCs in the BM of Zfp36l1fl/fl CD79aCre/+mice can be fully accounted for by defectivemigration of the newly
generated ASCs to the BM. (A) Schematic representation of the experimental setup for detection of the newly arrived NP-specific ASCs to the BM.
(B) Representative flow cytometry plots gated as in Fig. 1 D on CD138+NIP+IgG1+ cells and used for detection of newly generated (BrdU-high) NP-specific ASCs
and the established (BrdU-low) NP-specific ASCs in the spleen at day 4 following reimmunization with NP-KLH in alum (two top plots) and in the BM (two
bottom plots). (C and E) Frequency of CD138+NIP+IgG1+ cells of Zfp36l1fl/fl CD79a+/+ (closed circles) and Zfp36l1fl/fl CD79aCre/+ (open squares) or Zfp36l1fl/fl Cd23-
Cre+ (open squares) mice at day 4 after reimmunization; the numbers of all CD138+NIP+IgG1+ cells in the spleen (C) and BM (E) are normalized to the numbers of
all eFluor780− cells in the sample. (D, F, and G) As above, but the populations of CD138+NIP+IgG1+ cells are split on the basis of BrdU staining into the BrdU-
high NP-specific ASCs (D and F) and the BrdU-low NP-specific ASCs (G) and quantified in the spleen (D) and the BM (F and G). (H) The ratio of the number of
BrdU-low NP-specific ASCs to the number of BrdU-high NP-specific ASCs in the BM. For all plots in all panels, each symbol represents data from an individual
mouse, and lines represent means. For each Cre-expressing line, data are representative of two independent experiments (n ≥ 4; two-way ANOVA; the P values
shown are for the main genotype effect). For all flow cytometry plots, the numbers next to the enclosed areas (gates) represent percentages of the cells falling
into the gate, and the number in the bottom right corner shows the number of cells in the plot.
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demonstrate that a buildup of CD138+NIP+IgG1+ ASCs in the
spleens of Zfp36l1fl/fl CD79aCre/+ mice can be attributed to defec-
tive signaling downstream of an S1P receptor.
Defective egress of ASCs from the spleen of Zfp36l1fl/fl
CD79aCre/+ mice results in their increased cell death
Impaired egress from the spleen should result in a reduced
number of ASCs entering the bloodstream. To test this prediction
directly, we determined the number of CD138+NIP+IgG1+ cells in
the blood of control and Zfp36l1 cKO mice 3 d after reimmuniza-
tion by flow cytometry. Since the surface abundance of CXCR4
and CD267 is low on blood CD138+NIP+IgG1+ cells, we used the
transcription factor IRF4 as an additional marker for ASCs (Klein
et al., 2006; Sciammas et al., 2006; Fig. S3 A). We found a twofold
reduction in the number of CD138+NIP+IgG1+ cells in the blood of
Zfp36l1 cKO mice independent of the Cre system used to drive
Figure 3. Impaired accumulation of NP-specific ASCs in the BM of Zfp36l1fl/fl CD79aCre/+ mice results from a delayed egress from the spleen. (A)
Quantification of a transwell migration assay of CD138highB220low cells differentiated in vitro as described in Materials and methods. The number of cells
migrated toward three different concentrations of S1P in the lower chamber was normalized to the number of identically gated cells in the input sample. The
B cell cultures used in the transwell assay routinely contained 10–20% of CD138highB220low cells (two-way ANOVA was performed on the data for 10 nM and
50 nM S1P; n = 4 and n = 6; data pooled from two or three independent experiments; each data point is a mean of technical duplicate measurements of independent
biological samples, lines represent means, and the P value shown is for the main genotype effect for migration toward 10 nM and 50 nM S1P). (B) Quantification of a
transwell migration assay performed as in A but toward CXCL12 (Student’s t test; n = 6; data pooled from three independent experiments; each data point is a mean
of technical duplicate measurements of independent biological samples, and lines represent means). (C) Quantification of NP-specific ASCs (gated as
eFluor780−TCRβ−CD138+Irf4+NIP+IgG1+ cells; full gating is depicted in Fig. S3 A) in blood of Zfp36l1fl/fl CD79a+/+ (closed circles) and Zfp36l1fl/fl CD79aCre/+ (open squares) or
Zfp36l1fl/fl Cd23-Cre+ (open squares) mice at day 3 after reimmunization with NP-KLH. For each Cre-expressing line, data are pooled from two independent experiments.
For the plots in panels C, D, F, and G, each symbol represents data from an individual mouse, and lines representmeans (n ≥ 4; two-way ANOVA; the P value shown is for
the main factor “presence of Cre”). (D) Frequency of CD138+NIP+IgG1+ cells in the spleen of Zfp36l1fl/fl CD79a+/+ (closed circles) and Zfp36l1fl/fl CD79aCre/+ (open squares)
mice at days 3, 4, and 5 following reimmunization with NP-KLH expressed as numbers of CD138+NIP+IgG1+ cells normalized to the numbers of all eFluor780− cells (n ≥ 3;
two-way ANOVAwith Sidak’s correction for multiple testing; the P values shown are for the genotype factor for separate days). (E) Representative flow cytometry plots
gated as in Fig. 1 D on CD138+NIP+IgG1+ cells from Zfp36l1fl/fl CD79aCre/+ mice 3 d (left plot) and 5 d (right plot) after reimmunization with NP-KLH and used to identify
aCasp3+ cells. (F andG) Plots showing proportions of aCasp3+ cells in the population of CD138+NIP+IgG1+ cells identified as in Fig. 1 D, Fig. 3 E, and Fig. S3 B in the spleen
(F) and BM (G) for Zfp36l1fl/fl CD79a+/+ (closed circles) and Zfp36l1fl/fl CD79aCre/+ (open squares) mice taken at days 3, 4, 5, and 6 following reimmunization with NP-KLH.
Data are representative of at least two independent experiments (n ≥ 3; two-way ANOVA with Sidak’s correction for multiple testing; the P values shown are for the
genotype factor for separate days [F] or the P value shown is for the main genotype effect [G]). For all flow cytometry plots, the numbers next to the enclosed areas
(gates) represent percentages of the cells falling into the gate, and the number in the bottom right corner shows the number of cells in the plot.
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deletion of the Zfp36l1fl allele (Fig. 3 C). Importantly, the number
of CD138+NIP+IgG1+ cells recovered on day 3 from the spleens of
Zfp36l1fl/fl CD79aCre/+ mice was similar to that in control animals
(Fig. 3 D), arguing against an accelerated generation of ZFP36L1-
deficient ASCs as a cause for their marked accumulation on day
4 (Fig. 3 D). By day 5, however, the numbers of NP-specific ASCs
in Zfp36l1 cKO mice was not different from that of controls
(Fig. 3 D).
Because the number of antigen-specific ASCs in the BMof Zfp36l1
cKO mice at days 5 and 6 following reimmunization (Fig. 1 F) was
lower than that of controls, it is likely that the delayed egress
from the spleen resulted in their death, either in the spleen
or en route to the BM. To understand if CD138+NIP+IgG1+ cells
in Zfp36l1fl/fl CD79aCre/+ mice undergo apoptosis at increased
rates, we enumerated dying ASCs identified as being positive
for active caspase 3 (aCasp3+). Normally, the dead cells are
quickly eliminated from the spleen so that only ∼5% of
aCasp3+ cells can be found even in cell populations with a high
turnover, such as GC B cells (Mayer et al., 2017; Fig. S3 B).
From days 3 to 5 following reimmunization, control mice
showed a progressive buildup in the proportion of aCasp3+
cells among CD138+NIP+IgG1+ ASCs (Fig. 3, E and F), demon-
strating that transition of ASCs to the bloodstream is naturally
inefficient. Zfp36l1fl/fl CD79aCre/+ mice displayed an equal ac-
cumulation of aCasp3+ cells in the splenic CD138+NIP+IgG1+
compartment at day 3. However, at day 5, the day after the
peak response in Zfp36l1 cKO mice (Fig. 3 D), ∼10% of all NP-
specific ASCs were aCasp3+, a twofold increase compared
with control animals (Fig. 3 F and Fig. S3 C). Notably, the
percentage of apoptotic cells in the BMpopulation of CD138+NIP+IgG1+
cells was similar between Zfp36l1fl/fl CD79a+/+ and Zfp36l1fl/fl
CD79aCre/+ mice (Fig. 3 G). Cell death among BM NP-specific
ASCs showed an acceleration from days 5 to 6, demonstrating
that in the BM as well as the spleen, the appearance of aCasp3+
cells can overcome the processes leading to their elimination.
Nevertheless, ZFP36L1-deficient CD138+NIP+IgG1+ ASCs do
not exhibit a noticeably higher predisposition to cell death
once they reach the BM. Overall, these data demonstrate that a
generally inefficient egress of ASCs from the spleen is asso-
ciated with a high incidence of cell death and that ZFP36L1
promotes their prompt transition into the bloodstream, thereby
reducing inherently high attrition rates.
ZFP36L1 regulates genes involved in S1P receptor signaling
To establish candidate transcripts regulated directly by ZFP36l1,
we identified RNA molecules bound to ZFP36L1 at nucleo-
tide resolution using individual-nucleotide resolution cross-
linking and immunoprecipitation (iCLIP). Because the iCLIP
protocol for ZFP36L1 requires immunoprecipitation of a low-
abundance protein and application of highly stringent washes
to identify specific interactions, it necessitates the use of a
large number of cells and cannot be applied to ASCs. There-
fore, we used a previously published iCLIP dataset obtained
for LN FoB cells activated with LPS for 48 h (Galloway et al.,
2016) and RNA sequencing (RNA-seq) on similarly activated
FoB cells from Zfp36l1fl/fl CD79aCre/+ and Zfp36l1fl/fl CD79a+/+
mice.
Analysis of differences in transcript abundance by DESeq2
followed by pathway-enrichment analysis of 272 differentially
expressed genes (change >1.5-fold; adjusted P value <0.05; Table
S1) showed that many genes with altered transcript abundance
are involved in the regulation of cell motility, adhesion, and
migration (Fig. 4 A). Depending on the gene ontology (GO) term,
the binding of ZFP36L1 to the cognate transcripts can be detected
by iCLIP for up to half of the genes in the term (Fig. 4 A, blue
bars). Notably, we found that the transcripts for both S1PR1 and
for the kinase G protein–coupled receptor kinase 2 (GRK2) en-
coded by the gene Adrbk1 were more abundant in B cells from
Zfp36l1 cKO mice (Fig. 4, B and C). While iCLIP analysis failed to
uncover interaction between ZFP36L1 and S1pr1 transcripts, we
note several AU-rich elements in the 39 UTR of S1pr1 mRNA,
indicating a potential for direct regulation by ZFP36L1. A very
low abundance of S1pr1 mRNA in activated B cells likely renders
ZFP36L1 binding undetectable and makes the exact nature of
S1pr1 regulation in primary B cells difficult to ascertain. The
ZFP36L1-binding sequence in the 39 UTR of Adrbk1 mRNA
identified by iCLIP analysis exhibits a very high degree of con-
servation between mammalian species (Fig. 4 D), further sub-
stantiating direct regulation of the expression of this kinase by
ZFP36L1.
To investigate if ZFP36L1-deficient splenic ASCs have
increased expression of GRK2, the splenocytes taken 3 d after
reimmunization were stained intracellularly with anti-GRK2
antibodies. CD138+NIP+IgG1+ ASCs from Zfp36l1 cKO mice dem-
onstrated a small but consistent increase in the abundance of
GRK2 protein (Fig. 4, E and F), which was validated in inde-
pendent experiments with another antibody raised against a
different epitope of GRK2 (Fig. S4, A and B). A similar increase in
GRK2 level in the absence of ZFP36L1 was demonstrated for
in vitro–generated ASCs by both flow cytometry (Fig. S4 C) and
Western blotting (Fig. S4, D and E). GRK2 is primarily thought of
as a negative regulator of S1P receptor signaling in lymphocytes
(Arnon et al., 2011), and its elevated abundance can account for
the defective chemotactic response of ZFP36L1-deficient ASCs to
S1P. Dysregulation of other genes in ZFP36L1 cKOmice cannot be
excluded as a factor in impaired egress of ASCs from the spleen,
but their contribution is likely to be obscured by the impact of
increased GRK2.
Regulation of integrin expression on ASCs by ZFP36L1 at early
and late stages of GC response
Integrins have been extensively documented to play an impor-
tant role in the homing of cells to the BM. The integrin dimer
α4β1 and its ligand VCAM-1 are thought to be dominant mole-
cules as demonstrated for hematopoietic stem cells and B cells
(Berlin-Rufenach et al., 1999; Koni et al., 2001; Leuker et al.,
2001), while a requirement for the α4β7 dimer has also been
reported (Katayama et al., 2004). We found that mRNA for the
integrin chains α4, β1, and β7 was more abundant in ZFP36L1-
deficient B cells (Fig. S4, F–H). The transcripts for the α4 and
β1 chains were also identified by iCLIP analysis as bound by
ZFP36L1 at highly conserved regions of their 39 UTRs (Fig. 5, A
and B); however, binding to the β7 mRNA was undetectable,
suggesting an indirect regulation of the β7 chain by ZFP36L1.
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Weconsistently detected an increased number of CD138+NIP+IgG1+
ASCs with a high surface level of the α4β7 dimer in the
spleens of Zfp36l1 cKO mice (Fig. 5, C and D; and Fig. S4 I). As
expected, the α4 integrin chain was elevated on ZFP36L1-
deficient ASCs 14 d after immunization (Fig. 5 E), but we
observed no difference in expression of the β1 chain (Fig. 5 F).
The latter finding was somewhat perplexing, and we hy-
pothesized that regulation of the integrin chain β1 by ZFP36L1
becomes apparent later in the immune response. Indeed,
analysis of the β1 surface level on splenic NP-specific ASCs in
Zfp36l1fl/fl CD79aCre/+ mice at day 42 demonstrated a modula-
tion of its expression by ZFP36L1 (Fig. 5 H and Fig. S4 K), as
was the case for the integrin α4 chain (Fig. 5 G and Fig. S4 J).
Thus, ZFP36L1 limits surface levels of the integrin chains α4,
β1, and β7 on splenic ASCs, with regulation of the β1 chain
becoming obvious only later in the response.
VCAM-1 and fibronectin, ligands for the α4β1 and α4β7
dimers, can be detected in the red pulp (Lu and Cyster, 2002;
Liakka and Autio-Harmainen, 1992), potentially contributing to
retention of splenic ASCs with aberrantly high surface expression
Figure 4. ZFP36L1-deficient ASCs contain higher levels of GRK2. (A) GO terms enriched in gene set enrichment analysis performed on the genes dif-
ferentially expressed (DE) in ZFP36L1-deficient and ZFP36L1-sufficient B cells activated with LPS. For each term, the numbers in parentheses are the numbers
of all genes in the term followed by the adjusted P (padj) value. The numbers outside the gray bars represent the number of DE genes (padj < 0.05; fold change
>1.5), and the numbers inside the blue bars represent the numbers of direct targets of ZFP36L1 identified by iCLIP (padj < 0.05), all overlapping with the
corresponding GO terms. Under the conditions used, activated B cells undergo at most three cell divisions and do not contain any CD138highB220low cells.
(B and C) Abundance of mRNA for S1pr1 gene for S1PR1 (B) and Adrbk1 gene encoding GRK2 kinase (C) expressed as FPKM in the LPS-activated B cells from
Zfp36l1fl/fl CD79a+/+ (closed circles) and Zfp36l1fl/fl CD79aCre/+ (open squares) mice. Each symbol represents data from B cells of an individual mouse, lines
represent means, and P values are adjusted by the Benjamini-Hochburg method calculated with DESeq2. (D) Conservation of the sequence surrounding cross-
linked nucleotides in the 39 UTR of Adrbk1 transcripts among primates and rodents. Cross-linked nucleotides were visualized using the UCSC Genome Browser
(http://genome.ucsc.edu). In the gene diagram, the blue boxes denote exons, the thinner line denotes 39 UTR, and the thin lines show introns. Arrows identify
nucleotides cross-linked to ZFP36L1, and X indicates a nonconserved nucleotide. (E) An overlay of representative flow cytometry plots gated on
CD138+NIP+IgG1+ cells from the spleens of Zfp36l1fl/fl CD79a+/+ and Zfp36l1fl/fl CD79aCre/+ mice analyzed 3 d after reimmunization. Rabbit polyclonal antibody
against GRK2 was conjugated to Alexa Fluor 647. (F) A plot showing geometric mean fluorescent intensities (gMFIs) for the GRK2 signal in the population of
splenic CD138+NIP+IgG1+ cells as in panel E for Zfp36l1fl/fl CD79a+/+ (closed circles) and Zfp36l1fl/fl CD79aCre/+ (open squares) mice. Each symbol represents data
from an individual mouse, and lines represent means. Data for independent experiments are shown in Fig. S4 B (n ≥ 4 per experiment; the P value is for a
Student’s t test).
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of these integrins. Furthermore, because blood from the spleen
flows into the hepatic portal vein and through the liver, such
CD138+NIP+IgG1+ cells may also adhere more strongly to the
endothelial cells lining the blood vessels and enter the liver. To
explore this possibility, we enumerated NP-specific ASCs in the
livers of mice 14 d after immunization. The livers of Zfp36l1fl/fl
CD79aCre/+ mice showed a twofold increase in the number of
CD138+NIP+IgG1+ cells compared with the livers of Zfp36l1fl/fl
CD79a+/+mice (Fig. 5 I), demonstrating that a higher expression
of α4β1 and α4β7 dimers on the surface of splenic ASCs in
Zfp36l1 cKO mice may further reduce their chances of suc-
cessfully reaching the BM.
Figure 5. Increase in the surface expression of the integrin chains α4 and β1 on splenic ASCs in Zfp36l1fl/fl CD79aCre/+mice becomesmore pronounced
on ASCs generated late in the immune response and is associated with a partial retention of ASCs in the liver. (A and B) Conservation of the sequence
surrounding cross-linked nucleotides in the 39 UTRs of the Itga4 (A) and Itgb1 (B) transcripts among a selection of primates and rodents. Cross-linked nu-
cleotides were visualized using the UCSC Genome Browser (http://genome.ucsc.edu). In the gene diagram, the blue boxes denote exons, the thinner lines
denote 39 UTRs, and the thin lines show introns. Arrows identify nucleotides cross-linked to ZFP36L1. (C) Representative flow cytometry plot gated as in
Fig. 1 D on CD138+NIP+IgG1+ cells from the spleen of Zfp36l1fl/fl CD79a+/+ mice at day 4 after reimmunization. The number close to the enclosed area
shows the percentage of α4β7-high NP-specific ASCs and the number in the bottom right corner shows the number of cells in the plot. (D) Percentages
of cells with a high α4β7 surface abundance in the splenic populations of CD138+NIP+IgG1+ cells in Zfp36l1fl/fl CD79a+/+ (closed circles) and Zfp36l1fl/fl
CD79aCre/+ (open squares) mice at day 4 following reimmunization (n ≥ 3; two-way ANOVA; the P value shown is for the main genotype effect).
(E–H) Plots showing geometric mean fluorescent intensities (gMFIs) for the surface integrin α4 (E and G) and β1 (F and H) signals on the population of
CD138+NIP+IgG1+ cells from the spleens of Zfp36l1fl/fl CD79a+/+ (closed circles) and Zfp36l1fl/fl CD79aCre/+ (open squares) mice at day 14 (E and F) and day
42 (G and H) after primary immunization (n ≥ 3 per experiment; the P values are for a Student’s t test [E and F] or for the main genotype effect in a two-
way ANOVA on logarithmically transformed data [G and H]). Where it is not indicated otherwise data are representative of at least two independent
experiments. Exp, experiment. (I) Enumeration of CD138+NIP+IgG1+ cells (gated as eFluor780−TCRβ−CD138+CD267+NIP+IgG1+ cells) in the livers of
Zfp36l1fl/fl CD79a+/+ (closed circles) and Zfp36l1fl/fl CD79aCre/+ (open squares) mice at day 14 after primary immunization; the numbers of CD138+NIP+IgG1+
cells are calculated for whole livers. For all plots in all panels, each symbol represents data from an individual mouse, and lines represent means (the P
value is for a Student’s t test; n = 5; data pooled from two independent experiments).
Saveliev et al. Journal of Experimental Medicine 8 of 15
Bone marrow homing of plasma cells is controlled by ZFP36L1 https://doi.org/10.1084/jem.20200504
Dynamic regulation of CXCR4 and integrin expression on ASCs
during migration to the BM
As the degree of integrin β1 control by ZFP36L1 depends on the
time point in the primary immune response when ASCs are
generated (Fig. 5, F and H), we hypothesized that expression of
this integrin can increase progressively with maturation of the
GCs. To test this hypothesis, we simultaneously analyzed mice
that had an immune response lasting for 14 and 42 d (Fig. S5 A).
Indeed, the surface abundance of the integrins α4 and β1 was
higher on splenic CD138+NIP+IgG1+ ASCs recovered 42 d after
immunization than on ASCs recovered at day 14 (Fig. 6, A and B;
and Fig. S5, C and D).
BM CD138+NIP+IgG1+ ASCs had greater surface expression of
the integrins α4 and β1 than CD138+NIP+IgG1+ cells from the
spleen of the same mouse independently of the genotype (Fig. 6,
C and D). Regulation of integrin expression upon ASC transition
to the BMwas probed directly by pulse labeling developing ASCs
with 5-ethynyl-29-deoxyuridine (EdU) 2 d after reimmunization
and analysis of BM cells 2 d later (Fig. S5 E). A population of
newly immigrated EdU-high CD138+NIP+IgG1+ ASCs (Fig. S5 F)
had a lower level of integrin β1 on the surface compared with
that of the established EdU-low ASCs (Fig. 6 E). Interestingly, the
α4β7 dimer displayed an opposite pattern of surface expression
(Fig. 6 F), while the levels of integrin α4 appeared to be largely
unchanged (Fig. 6 G). Together, these results demonstrate that
maturation of ASCs in the BM is associated with an increase in
the surface integrin β1 and down-regulation of the α4β7 dimer.
However, ZFP36L1 is not required for integrin regulation once
the ASCs reach the BM (Fig. 6, E and F).
When comparing splenic and BMASCs at days 14 and 42 after
immunization, we observed that CXCR4 is more abundant on
splenic CD138+NIP+IgG1+ ASCs prepared at day 42 than on BM
ASCs recovered at day 14 (Fig. 6 H and Fig. S5 B), while these two
ASC populations are remarkably similar as far as surface ex-
pression of the integrins α4 and β1 is concerned (Fig. 6, I and J).
Given the prominent role that these molecules are thought to
play in guiding an ASC to its survival niche, these observations
suggest a possible explanation for the substitution of NP-specific
ASCs established in the BM early in the response with the newly
immigrated ASCs generated at more advanced stages, the latter
being enriched for clones secreting high-affinity antibody.
Consistent with the greater control that ZFP36L1 exerts over
expression of the integrins α4 and β1 in ASCs formed later in the
immune response (Fig. 5, G and H), accumulation of ASCs in the
BM of control and Zfp36l1 cKO mice followed different patterns
for the high- and low-affinity clones (Fig. S5, G and H). Taken
together, these data show that surface expression of the integrin
chains α4, β1, and β7 on ASCs undergoes dynamic changes as
ASCs migrate from the spleen to the BM. However, their ex-
pression on splenic ASCs has to be tightly regulated by ZFP36L1
to facilitate their homing to the BM, especially at the late stages
of the primary immune response.
Discussion
While ZFP36L1 was previously reported to be required for the
localization and survival of MZ B cells, it is thought to do so
mainly through control of transcription factors such as IRF8 and
KLF2, which, when elevated, impose FoB cell–like properties on
MZ B cells (Newman et al., 2017). In the present study, ZFP36L1
is shown to directly limit the abundance of GRK2 and of the
integrins α4 and β1 in splenic ASCs by binding and restricting
levels of their mRNAs. Increased GRK2 results in impaired mi-
gration toward S1P and, as a consequence, defective egress of
ASCs from the spleen. At the same time, elevated surface ex-
pression of integrins α4, β1, and β7 is associated with increased
retention of ASCs in the liver and likely contributes to their
delayed exit from the spleen. We found that ASC arrival to the
BM is accompanied by reduced surface expression of the α4β7
dimer and increased α4 and β1 integrins, presumably reflecting
processes leading to eventual lodgement of an ASC in the BM
niche. However, as the phenotype of Zfp36l1 cKO mice demon-
strates, a premature increase in α4β1 surface abundance and
an abnormally high level of α4β7 led to enhanced retention of
transitory ASCs in the liver and presumably other sites of
VCAM-1, MAdCAM-1, and fibronectin expression.
The integrin dimer α4β1 is thought to be the principal guid-
ance receptor for homing to the BM. However, a role for the
α4β7 integrin in this process has also been suggested by trans-
plantation experiments using α4β7-blocking antibody or
β7-deficient hematopoietic stem cells (Katayama et al., 2004;
Murakami et al., 2016). Furthermore, findings in mice with
B cell–specific deletion of the transcriptional factor KLF2 indi-
rectly implicated the α4β7 integrin in ASC migration. In these
mice, FoB cells have reduced expression of the α4β7 integrin,
and they respond to a T cell–dependent antigen by generating a
normal number of splenic ASCs, yet these do not accumulate in
the BM (Hart et al., 2011; Winkelmann et al., 2011). While we
consistently found an increase in surface expression of the β7
integrin on ZFP36L1-deficient ASCs, we did not detect an in-
crease in KLF2 abundance (data not shown). These observations
suggest that in ASCs, KLF2 is not limiting as far as transcription
of the β7 integrin is concerned, and other transcriptional fac-
tor(s) must be involved.
The reported requirement for strict temporal control of gene
expression by ZFP36L1 is in close accord with the mechanism
described for enforcement of quiescence by ZFP36L1 and its
paralogue ZFP36L2 during the pre–B cell receptor checkpoint
(Galloway et al., 2016). In both developmental transitions, de-
mands for a prompt and reversible modulation of gene expres-
sion seem to have rendered posttranscriptional regulation
superior from an evolutionary perspective to control mediated
bytranscriptional factors. The evolutionary advantage for strict
control of integrin α4β1 expression by ZFP36L1 comes into sharp
relief at later stages of the immune response, when splenic ASCs
display increased expression of the α4 and β1 chains compared
with ASCs formed early in the GC reaction. Considering the
likelihood that mature GCs predominantly produce ASCs se-
creting high-affinity antibody, the BM homing of such clones
should be affected to a greater extent by ZFP36L1 deficiency than
the homing of low-affinity clones is. This supposition agrees
with our observation of different accumulation patterns for low-
affinity and high-affinity ASCs in the BM of control and Zfp36l1
cKO mice.
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The elevated expression of CXCR4 and the α4 and β1 integrin
chains on ASCs formed late in the response offers a possible
explanation as to why such cells might have a competitive edge
when it comes to displacement of ASCs already established in
the BM niche, a mechanism suggested for affinity maturation in
the BM ASC compartment (Radbruch et al., 2006). While at
present the only evidence for displacement comes from the
appearance of diverse ASCs in the blood of human subjects after
vaccination (Odendahl et al., 2005), it is consistent with gradual
accumulation and increase in the complexity of V gene muta-
tions in BM ASCs after immunization with NP conjugated to a
protein carrier from day 12 onward (Smith et al., 1997; Takahashi
et al., 1998). Such a mechanism, however, has been difficult to
conceptualize in molecular terms, since high-affinity ASCs lack
an obvious means to convert the superior affinity of their re-
ceptor to their advantage as the maturation of ASCs leads to a
reduction in surface Ig and its associated signal transduction
components.
The temporal difference in the surface abundance of CXCR4
and of the α4 and β1 integrins described here circumvents this
problem. It also suggests a shift in emphasis in the displacement
process from one instructed by B cell receptor–mediated gene
Figure 6. BM CD138+NIP+IgG1+ cells display elevated levels of the integrins α4 and β1 on their surface compared with splenic CD138+NIP+IgG1+ cells
from the same animal. (A and B) Plots showing geometric mean fluorescent intensities (gMFIs) for surface integrin α4 (A) and β1 (B) signals on the population
of CD138+NIP+IgG1+ cells from the spleens of Zfp36l1fl/fl CD79a+/+ mice at days 14 and 42. The staining and analysis were performed on the same day with the
same flow cytometer settings; the data for two independent experiments are shown (n ≥ 3 per experiment; two-way ANOVA on logarithmically transformed
data; the P values shown are for the day factor). (C and D) Plots showing gMFI for surface integrin α4 (C) and β1 (D) signals on the population of
CD138+NIP+IgG1+ cells from the spleens and BM of individual Zfp36l1fl/fl CD79a+/+ (closed circles) and Zfp36l1fl/fl CD79aCre/+ (open squares) mice analyzed at day
42 (n ≥ 4; two-way ANOVA; the P values shown are for the organ factor). (E–G) Plots showing percentages of cells with a high α4β7 surface abundance (F) and
gMFI for surface level of the integrin chains β1 (E) and α4 (G) among both EdU-high NP-specific ASCs and EdU-low NP-specific ASCs in the BM of mice of both
genotypes at day 4 after reimmunization. Populations were identified as depicted in Fig. S5 F (n = 3; two-way ANOVA; the P value shown is for the factor “type
of ASC”). (H–J) Plots showing gMFIs for CXCR4 (H) and for the surface integrin α4 (I) and β1 (J) signals on the population of CD138+NIP+IgG1+ cells from the
spleen and BM of individual Zfp36l1fl/fl CD79a+/+ mice at day 14 and day 42 after primary immunization (n ≥ 4 per time point; two-way ANOVA; the P values
shown are for the day factor). For all plots in all panels, each symbol represents data from an individual mouse, and lines represent means. Where it is not
indicated otherwise, data are representative of at least two independent experiments. Exp, experiment; Spl, spleen; hi, high.
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expression changes to one of stochastic nature, where proba-
bility of the successful event depends on relative levels of the
key migratory molecules likely to be defined by maturation
status of the GCs. Long-term ASCs of various specificities es-
tablished in the BM during previously resolved infections are
expected to have the highest surface abundance of CXCR4 and of
the integrins α4 and β1; accordingly, they are less likely to be
substituted by arriving ASCs with fresh specificities generated
in the ongoing response. Such a model would also agree with
recent work that demonstrated a tendency for the majority of
BM long-term plasma cells to be generated late in the response
and documented changes in gene expression by early and late
GC B cells (Weisel et al., 2016). The study reported that, among
other transcripts, CXCR4 mRNA is increased in late GC B cells, a
difference that will have to be explored further as it may result
from varying proportions of centrocytes and centroblasts in the
GCs recovered at different stages of the response. The challenge
for the future will be to establish which gene products and
signaling pathways drive the difference in the surface pheno-
type of ASCs formed early and late in the immune response.
Materials and methods
Mice, immunization, and in vivo treatment
Mice on the C57BL/6 background were obtained by crosses of
mice carrying the following alleles: Zfp36l1tm1.1Tnr (Hodson et al.,
2010), CD79atm1(cre)Reth (Hobeika et al., 2006), and Tg(Fcer2a-cre)
5Mbu (Kwon et al., 2008). Mice carrying the targeted alleles
were backcrossed with C57BL/6 mice for at least 10 generations
and then intercrossed to generate experimental mice. Mice were
bred and maintained in the Babraham Institute Biological Sup-
port Unit. Since the opening of this barrier facility in 2009, no
primary pathogens or additional agents listed in the Federation
of European Laboratory Animal Science Associations recom-
mendations have been confirmed during health monitoring
surveys of the stock holding rooms. Ambient temperature was
∼19–21°C, and relative humidity was 52%. Lighting was provided
on a 12-h light:12-h dark cycle, including 15-min “dawn” and
“dusk” periods of subdued lighting. After weaning, mice were
transferred to individually ventilated cages with one to five mice
per cage. Mice were fed CRM (P) VP diet (Special Diet Services)
ad libitum and received seeds (e.g., sunflower, millet) at the time
of cage cleaning as part of their environmental enrichment. All
mouse experimentation was approved by the Babraham Insti-
tute Animal Welfare and Ethical Review Body. Animal hus-
bandry and experimentation complied with existing European
Union and UK Home Office legislation and local standards. All
mice used experimentally were between 8 and 12 wk of age and
were age and sex matched within experiments; although no sex-
associated differences were observed in the results obtained,
control mice were sex- and age-matched littermates negative for
a Cre-carrying allele.
BrdU (Sigma) was administered at 0.8 mg/ml in drinking
water containing 1% sucrose (Thermo Fisher Scientific) the day
after reimmunization and for the duration of the secondary
response. To label the cells with EdU (Thermo Fisher Scientific),
the mice were injected i.p. with 1 mg EdU in 200 µl PBS 2 d after
reimmunization. For primary immunization, mice were injected
i.p. with 200 µl containing 100 µg NP-KLH (Biosearch Tech-
nologies) precipitated in alum (Universal Biologicals). For re-
immunization, 50 µg NP-KLH was either precipitated in alum
for BrdU- and EdU-labeling experiments or diluted in PBS before
injection i.p.
ELISPOT and ELISA
For ELISPOT, MultiScreen HA mixed cellulose ester plates
(Millipore) were coated with NP23-BSA (Biosearch Technolo-
gies) or NP2-BSA (conjugated in-house) in PBS, washed, and
blocked with complete medium before applying serially di-
luted cell suspensions and incubating overnight under 5% CO2
at 37°C in IMDM, 10% FCS, 2 mM GlutaMAX, and 50 µM 2-
mercaptoethanol. Cells secreting anti-NP antibody were vi-
sualized with horseradish peroxidase–conjugated anti–mouse
IgG1 antibody (SouthernBiotech) followed by an AEC staining
kit (Sigma). The numbers of ASCs were quantified using Im-
munospot S6 Analyzer (Cellular Technology Limited). ELISA
was performed essentially as described previously (Newman
et al., 2017).
Cell preparations and flow cytometry analysis
Preparation of cell suspensions from the spleen and BM and
antibody staining for surface markers were performed es-
sentially as described previously (Galloway et al., 2016). Er-
ythrocytes in spleen samples were lysed by incubating cell
suspensions for 30 s at room temperature in 1.5 ml ACK buffer
(150 mM NH4Cl, 10 mM KHCO3, and 0.1 mM Na2EDTA, pH
7.2–7.4). Lysis was stopped by adding 10 ml of RPMI-1640
(Sigma) and 5% FCS.
A full list of antibodies and other reagents is provided in
Table S2. The antibody against GRK2 (OriGene) was labeled
using an Alexa Fluor 647 Antibody Labeling Kit from Molecular
Probes (Thermo Fisher Scientific) according to the manu-
facturer’s instructions. To stain for intracellular proteins, cells
were first stained for surface markers, and fixable viability dye
eFluor780 (eBioscience) was used to identify the cells with an
intact plasma membrane. The cells were then fixed in BD Cy-
tofix/Cytoperm (Becton Dickinson) on ice for 30 min, washed in
BD Perm/Wash buffer, and either frozen at −80°C in 10% DMSO
in FCS or stained overnight at 4°C in BD Perm/Wash buffer
containing the corresponding antibody and NIP conjugated to
biotin through BSA, followed by washing and staining for
40 min at 4°C with a mix of streptavidin conjugated to PE-Cy7
and anti-mouse IgG1 antibody. For identification of BrdU+ cells,
the samples were stained for surface markers, then fixed and
stained with NIP-biotin and IgG1 antibody followed by fixation
and detection of BrdU with the FITC BrdU Flow Kit (Becton
Dickinson) according to the manufacturer’s instructions. EdU
incorporation was detected with the Click-iT EdU Alexa Fluor 488
Flow Cytometry Assay Kit (Thermo Fisher Scientific). Staining
with the antibody against aCasp3+ was performed overnight
as described above. eFluor780−CD4−CD8−IgD−CD138+CD267+ cells
that stained high for intracellular IgG1 but not for NIP were
used as a reference population when identifying aCasp3+ cells
among eFluor780−CD4−CD8−IgD−CD138+CD267+NIP+IgG1+ cells.
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The threshold for aCasp3+ cells was then verified against a
similar threshold for GC B cells (Fig. S3 B). After staining, ∼5 ×
106 events were acquired on a Fortessa (Becton Dickinson) flow
cytometer, and the data were analyzed using Flowjo software
(Becton Dickinson).
To prepare liver lymphocytes, the blood from the liver was
flushed by injecting PBS into the hepatic portal vein before
collection of the organ. The livers were homogenized in gen-
tleMACS (Miltenyi Biotec) using two cycles of a preset program
for spleen. Cell suspensions were loaded onto a discontinuous
Percoll gradient (37.5%/72%) and centrifuged at room tempera-
ture at 900× g for 20 min. The lymphocytes were collected from
the interface, washed, and stained for surface markers including
NK1.1, TCRβ, CD138, CD267, and CXCR4 as above. Before fixa-
tion, one tenth of the cell suspension was taken, washed, mixed
with a defined number of AccuCount Beads (Spherotech), and
acquired on a flow cytometer. Nine tenths of the cell suspension
was fixed and stained for intracellular NIP and IgG1 and ana-
lyzed as above. The absolute number of CD138+NIP+IgG1+ cells in
the whole sample before fixation was calculated on the basis of
counts for TCRβ+ cells in the aliquot taken before fixation and in
the aliquot that received complete staining.
Blood, taken by cardiac puncture, was collected into tubes
containing 300 µl heparin sodium (1,000 U in 1 ml; Wockhardt
UK Ltd). The volumes of collected samples were measured, and
erythrocytes were lysed by incubating cell suspensions for 30 s
in 4 ml ACK buffer twice; lysis was stopped each time by adding
40 ml RPMI 1640 (Sigma), 5% FCS. The cells were stained for
surface markers including CD4, TCRβ, CD138, and CD267 as
above. The samples were split into two aliquots and processed as
described above for the liver samples. The absolute number of
CD138+NIP+IgG1+ cells in 1 ml blood was calculated on the basis
of counts for CD4+TCRβ+ cells in the aliquot taken before fixa-
tion and in the aliquot that received complete staining.
Immunostaining of spleen sections
3–4-mm pieces of spleen were fixed in PLP (2% paraformalde-
hyde, 37.5 mMNa2HPO4, 75 mM L-lysine, and 10 mMNaIO4, pH
7.4) for 4 h at 4°C followed by washes in 30% sucrose in PBS
overnight at 4°C. Tissue was frozen in O.C.T. compound on dry
ice and sectioned on the cryostat (8 µm thick). Sections were air-
dried overnight at room temperature and stored at −20°C. Before
staining, the sections were rehydrated in PBS, 0.5% Tween20
and sequentially blocked with PBS, 2% BSA, 2% normal rat se-
rum, and the Streptavidin/Biotin Blocking Kit (Vector Labora-
tories). Sections were stained in PBS containing 2% BSA, NIP,
and antibodies against IgD, CD169 (MOMA-1), and IgG1 at 4°C
overnight in a humidified chamber, followed by a 2-h incubation
with streptavidin conjugated to Alexa Fluor 555. Slides were
washed in PBS, 0.5% Tween20 and mounted in Vectashield
Antifade Mounting Medium (Vector Laboratories). Images were
acquired at 20× magnification using a Zeiss 780 point-scanning
confocal microscope.
Cell purification and cultures
FoB cells from peripheral and mesenteric LNs were isolated by
negative selection. Single-cell suspensions were incubated with
biotin-conjugated antibodies against CD5, CD43, Mac, and Ter119
and were then washed and incubated with streptavidin-conjugated
magnetic beads (Dynabeads; Thermo Fisher Scientific). Purity of
CD19+ cells (typically >95%) was confirmed by flow cytometry. For
RNA-seq analysis FoB cells were cultured for 48 h in RPMI 1640
medium, 10% FCS, 2 mM GlutaMAX, 1 mM Na-Pyruvate,
50 µM 2-mercaptoethanol containing 10 µg/ml LPS, 10 ng/ml
IL4, and 10 ng/ml IL5.
For quantification of GRK2 by Western blotting, FoB cells
were purified from spleens essentially as above with the ex-
ception of additionally using biotin-conjugated antibodies against
CD1d to deplete MZ B cells. Content of MZ B cells after such de-
pletion was comparable between B cell preparations for spleno-
cytes of both genotypes (typically 1–2%). Following culturing of
B cells for 96 hwith 3.5 µg/ml LPS, 10 ng/ml IL4, and 10 ng/ml IL5,
eFluor780lowCD138highB220low cells were sorted using a BD FACS-
Aria III or a BD FACSAria Fusion.
Western blotting
Sorted CD138highB220low cells were washed with PBS and lysed
in RIPA buffer (50 mM Tris-HCl, pH 8.0, 150 mM NaCl, 1.0%
Igepal CA-630 [NP-40], 0.5% sodium deoxycholate, 0.1% sodium
dodecyl sulfate, and 2 mM EDTA) containing protease inhibitors
(Sigma) for 10 min on ice. After debris was spun for 12 min at
20,000× g at 4°C, the protein content in the lysates was mea-
sured with a BCA Protein Assay kit (Pierce). Western blotting of
40 µg of protein for each sample and subsequent signal detection
were performed essentially as described previously (Saveliev
et al., 2009).
In vitro migration
Transwell plates (pore size, 5 µm; Costar) were preincubated
with chemotaxis buffer (RPMI 1640, 10 mM Hepes, and 1 mM
glutaMAX) containing 0.4% BSA at 37°C for 1 h. Plasmablast-like
cells obtained by culturing LN FoB cells (see Cell purification and
cultures) for 96 hwith 3.5 µg/ml LPS, 10 ng/ml IL4, and 10 ng/ml
IL5 were washed three times with chemotaxis buffer containing
0.12% BSA and preincubated at 37°C for 50 min. 250 ng/ml
CXCL12 (Peprotech) or S1P (Sigma) at 10 nMor 50 nMwas added
to the lower chamber, whereas plasmablast-like cells were
added to the upper chamber (0.8 × 106 cells/well). Cells were
allowed tomigrate for 3 h at 37°C through the transwell insert. Cells
that had migrated into the lower chamber were collected, a defined
number of AccuCount Beads (Spherotech)was added to the samples
to allow quantification of cell number, and cells were stained with
eFluor780 and antibodies against B220, CD138, CD267, and IgG1. The
number of eFluor780−B220lowCD138highCD267+ cells in each sample
was quantified by flow cytometry analysis. Efficiency of migration
was then expressed as the percentage of cells in the lower chamber
as related to the number of identically gated cells in the input
population.
High-throughput sequencing and library preparation
RNA-seq libraries were prepared using an ARTseq Ribosome
Profiling Kit (Epicentre; Illumina) according to the manu-
facturer’s instructions. LPS-activated B cells (see Cell purifica-
tion and cultures) were treated with 100 µg/ml cycloheximide
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for 3 min immediately before preparation of cell extracts. 100-bp
single-end sequencing of RNA-seq libraries was performed using
the HiSeq2500 (Illumina). iCLIP libraries (Galloway et al., 2016)
were prepared as described (Vogel et al., 2016).
Bioinformatic analysis of RNA-seq data
Quality of sequencing data was assessed using FastQC. Reads
aligning to ribosomal RNA and Ig loci were filtered out before
the analysis. Reads were mapped to mouse genome (GRCm38)
using Tophat2 (Kim et al., 2013). Reads aligning to genes were
counted using HTSeq-count (Anders et al., 2015), and analysis
of differentially expressed genes was performed using the
DESeq2 (Love et al., 2014). Cuffnorm (Trapnell et al., 2010)
was used to calculate fragments per kilobase of transcript per
million mapped reads (FPKM) values. iCLIP sequencing data
were visualized using genome assembly GRCm38 with the
University of California Santa Cruz (UCSC) genome browser
(Kent et al., 2002). GO term–enrichment analysis was per-
formed with gProfiler (Raudvere et al., 2019). A list of genes
with average FPKM value across all samples of at least 0.06
and at least one read in each sample was used as a background
list of genes. Benjamini-Hochberg false discovery rate was
used to correct for multiple testing, and only the terms con-
taining 10–700 genes were considered. Where several signif-
icantly enriched terms are hierarchically related, the topmost
term is presented in Fig. 4.
Data availability
The RNA-seq data are available in the Gene Expression Om-
nibus database under the accession codes GSE146073 (tran-
scriptome of ZFP36L1-sufficient and ZFP36L1-deficient FoB cells)
and GSE78249 for the activated B cell iCLIP (Galloway et al.,
2016).
Statistical analysis
The test used and sample sizes are indicated in the figure
legends. The Student’s t test used was an unpaired two-tailed
test. When the variable displayed a very large range, the
heterogeneous random errors were stabilized by logarithmic
transformation of the data before analysis. All statistical anal-
yses were performed using Prism 8.3.0 software (Graph-
Pad). Statistical tests for data generated by high-throughput
sequencing are described in Bioinformatic analysis of RNA-
seq data.
Online supplemental material
Fig. S1 shows representative flow cytometry plots of NP-specific
GC B cells and a plot with their frequency, ratio of high-affinity
NP antibody to NP antibody with all affinities in sera, serum
dilutions required to reach a 50% inhibitory concentration,
and enumeration of splenic ASCs. Fig. S2 shows representa-
tive flow cytometry plots for newly formed and established
CD138+NIP+IgG1+ cells, frequencies of the newly generated
CD138+NIP+IgG1+ cells, and representative images of splenic
sections from immunized mice. NIP+IgG1+ cells in the spleens
of Zfp36l1fl/fl CD79aCre/+ mice tend to accumulate normally near
venous sinuses and vessel-associated fibers in the red pulp.
Fig. S3 shows representative flow cytometry plots used for
identification of CD138+NIP+IgG1+ cells in the blood and for
identification of aCasp3+ cells and a plot with frequencies of
aCasp3+ CD138+NIP+IgG1+ cells obtained in an independent
experiment. The approach used to set up a threshold for
quantification of aCasp3+ cells among NP-specific ASCs. Fig.
S4 shows representative flow cytometry plots for GRK2 signal
and a plot with its quantification obtained in an independent
experiment, plots with quantification of GRK2 abundance in
in vitro–generated plasmablast-like cells and a representative
Western blot, abundance of mRNA for the Itga4, Itgb1, and
Itgb7 genes, a plot with frequencies of α4β7high CD138+NIP+IgG1+
cells, and representative flow cytometry plots for α4 and
β1 signals. ZFP36L1-deficient splenic ASCs show an increased
surface expression of the integrin chains α4, β1, and β7. Fig. S5
shows a schematic representation of the experiments for
analysis of ASCs recovered in responses lasting for 14 and 42 d
and for labeling of ASCs newly arrived to the BM, representative
flow cytometry plots for CXCR4, α4 and β1 signals and those used
for identification of EdU+ CD138+NIP+IgG1+ cells, and plots with
enumeration of BM ASCs. Table S1 provides the details of dif-
ferentially expressed genes between LPS-activated B cells from
ZFP36L1 cKO animals and control animals. Table S2 lists the
antibodies and other reagents used in this study. Different
patterns of accumulation in the BM for high- and low-
affinity ASCs.
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and plasma cell homing controlled by Krüppel-like factor 2. Proc. Natl.
Acad. Sci. USA. 108:710–715. https://doi.org/10.1073/pnas.1012858108
Xu, S., X. Ou, J. Huo, K. Lim, Y. Huang, S. Chee, and K.P. Lam. 2015. Mir-17-92
regulates bone marrow homing of plasma cells and production of immu-
noglobulin G2c. Nat. Commun. 6:6764. https://doi.org/10.1038/ncomms7764
Saveliev et al. Journal of Experimental Medicine 15 of 15
Bone marrow homing of plasma cells is controlled by ZFP36L1 https://doi.org/10.1084/jem.20200504
Supplemental material
Figure S1. The GC reaction is not affected in the absence of ZFP36L1 in B cells. (A) Representative flow cytometry plots used for detection of NP-specific
GC B cells; surface NIP+, IgG1+ cells (middle plot) were identified in the population of CD95+CD38low GC cells (left plot, pregated on
eFluor780−IgM−IgD−CD90.2− cells), and the absence of such NIP+, IgG1+ cells was confirmed in a nonimmunized mouse (right plot). (B) Frequency of surface
NIP+IgG1+ GC cells in the spleens of Zfp36l1fl/fl CD79a+/+ (closed circles) and Zfp36l1fl/fl CD79aCre/+ (open squares) mice at days 14 and 21 after immunization; the
number of surface NIP+IgG1+ GC cells in the spleen is normalized to the number of all live CD19+ cells (n ≥ 4; two-way ANOVA on logarithmically transformed
data; the P value shown is for the main genotype effect). For all plots in all panels, each symbol represents data from an individual mouse, and lines represent
means. Data are representative of two independent experiments. (C) Ratio of anti-NP2 IgG1 to anti-NP20 IgG1 (NP2/NP20) antibody in the serum of Zfp36l1fl/fl
CD79a+/+ (closed circles) and Zfp36l1fl/fl CD79aCre/+ (open squares) mice measured by ELISA at various time points after immunization with NP-KLH in alum.
(D) ELISPOT analysis of NP-specific ASCs in Zfp36l1fl/fl CD79a+/+ and Zfp36l1fl/fl CD79aCre/+mice. Enumeration of ASCs secreting anti-NP23 (high and low affinity)
IgG1 antibody in the spleen (n ≥ 4; two-way ANOVA on logarithmically transformed data; the P value shown is for the main genotype effect). (E and F) Titers of
anti-NP2 IgG1 (E) and anti-NP20 IgG1 (F) antibody in the serum of Zfp36l1fl/fl CD79a+/+ (closed circles) and Zfp36l1fl/fl CD79aCre/+ (open squares) mice (each data
point is a mean ± SD of dilution for a 50% inhibitory concentration for n = 5 mice for each genotype; two-way ANOVA on logarithmically transformed data with
Sidak’s correction for multiple testing; the P value shown is for the genotype effect for day 56). For all flow cytometry plots, the numbers next to the enclosed
areas (gates) represent percentages of the cells falling into the gate, and the number in the bottom right corner shows the number of cells in the plot. SA,
streptavidin; PE, R-phycoerythrin.
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Figure S2. Newly generated (BrdU-high) NP-specific ASCs do not appear in the BM before day 4 after reimmunization. (A and B) An overlay of
representative flow cytometry plots of BrdU-high (shaded histogram) and BrdU-low (black line) CD138+NIP+IgG1+ cells from the BM of Zfp36l1fl/fl CD79a+/+ (A)
and Zfp36l1fl/fl CD79aCre/+ (B) mice analyzed at day 4 after reimmunization. (C and D) Frequency of the newly generated (BrdU-high) CD138+NIP+IgG1+ cells in
the spleen (C) and BM (D) of Zfp36l1fl/fl CD79a+/+ mice at days 3, 4, and 6 after reimmunization. The numbers of the BrdU-high CD138+NIP+IgG1+ cells are
normalized to the numbers of all eFluor780− cells in the sample. For all plots in all panels, each symbol represents data from an individual mouse, lines
represent means, and data are representative of two independent experiments. (E and F) Immunofluorescence analysis of spleen sections from a Zfp36l1fl/fl
CD79a+/+ mouse (E) and a Zfp36l1fl/fl CD79aCre/+ mouse (F) at day 4 following secondary immunization. The sections were stained with anti-IgG1 (blue), anti-
CD169 (MOMA-1, green), and anti-IgD (gray) antibody and NIP-BSA-bio Streptavidin Alexa Fluor 555 (red). The images are representative of sections taken
from four mice for each of the genotypes. Original magnification, 20×; scale bars, 100 µm.
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Figure S3. The approach used in identification of NP-specific ASCs in the blood. (A) A sequence of flow cytometry plots used to identify NP-specific ASCs
in the blood. eFluor780−TCRb− cells high for the intracellular NIP and IgG1 signals show a distinct population of CD138+Irf4hi cells (rightmost plot). The number
of such eFluor780−TCRb−CD138+Irf4hiNIP+IgG1+ cells per 1 ml blood was calculated as described in Materials and methods. (B) Flow cytometry plots showing
proportions of aCasp3+ cells found in various splenic cell populations of the same mouse. eFluor780−CD4−CD8−IgD−CD138+CD267+ cells high for intracellular
IgG1 but not for NIP were generally found to have very few aCasp3+ cells, presumably due to the fact that lower rates of their generation were not exceeding
the rates of their elimination from the tissue. For all flow cytometry plots, the numbers next to the enclosed areas (gates) represent percentages of the cells
falling into the gate, and the number in the bottom right corner shows the number of cells in the plot. Arrows denote the hierarchical relationship between the
cell populations. (C) A plot showing proportions of aCasp3+ cells in the population of CD138+NIP+IgG1+ cells identified as in Fig. 1 D, Fig. 3 E, and Fig. S3 B in the
spleens of Zfp36l1fl/fl CD79a+/+ (closed circles) and Zfp36l1fl/fl CD79aCre/+ (open squares) mice taken at day 5 following reimmunization with NP-KLH in an
independent experiment. Each symbol represents data from an individual mouse, and lines represent means (n ≥ 5; the P value is for a Student’s t test). Pos,
positive.
Saveliev et al. Journal of Experimental Medicine S3
Bone marrow homing of plasma cells is controlled by ZFP36L1 https://doi.org/10.1084/jem.20200504
Figure S4. GRK2 abundance is increased in NP-specific splenic ASCs in Zfp36l1fl/flCD79aCre/+ mice. (A) An overlay of representative flow cytometry plots
gated on CD138+NIP+IgG1+ cells from the spleens of Zfp36l1fl/fl CD79a+/+ and Zfp36l1fl/fl CD79aCre/+mice analyzed at days 3 and 5 after reimmunization. Antibody
against GRK2 used in these experiments was from Cell Signaling Technology and was used in combination with the secondary Alexa Fluor 647–conjugated
donkey anti-rabbit IgG antibody. (B) A plot showing geometric mean fluorescent intensities (gMFIs) for GRK2 signal in the population of CD138+NIP+IgG1+ cells.
Each symbol represents data from an individual mouse, and lines represent means. Data are from independent experiments performed in confirmation of
Fig. 4 F (n ≥ 4 per experiment; two-way ANOVA; the P value shown is for the main genotype effect). (C) A plot showing gMFIs for GRK2 signal in the population
of CD138highB220low cells differentiated in vitro. GRK2 was detected with antibody from OriGene followed by the secondary Alexa Fluor 647–conjugated
donkey anti-rabbit IgG antibody. Each symbol represents data from an individual mouse, and lines represent means. Data are from two independent ex-
periments (n = 3 per experiment; two-way ANOVA; the P value shown is for the main genotype effect). (D) Representative Western blot of total protein
extracts of CD138highB220low cells differentiated in vitro and sorted by a flow cytometer as described in Materials and methods. The upper panel shows the
membrane incubated with antibody against GRK2, and the lower panels show the samemembrane incubated with antibody against β-actin and against GAPDH.
(E) A plot showing relative abundance of GRK2 as determined by a ratio of the signal for the band corresponding to GRK2 to the signal for β-actin (a comparable
result was obtained with GRK2 signal normalized to that of GAPDH; data not shown). Each symbol represents data from an individual mouse, and lines
represent means (n ≥ 2 per experiment; two-way ANOVA; the P value shown is for the main genotype effect). (F–H) Abundance of mRNA for the Itga4 (F), Itgb1
(G), and Itgb7 (H) genes in LPS-activated B cells from Zfp36l1fl/fl CD79a+/+ (closed circles) and Zfp36l1fl/fl CD79aCre/+ (open squares) mice. Each symbol represents
data from B cells of an individual mouse, and lines represent means. P values calculated with DESeq2 are adjusted by the Benjamini-Hochburg method.
(I) Percentages of cells with a high integrin α4β7 surface abundance in the splenic populations of CD138+NIP+IgG1+ cells in Zfp36l1fl/fl CD79a+/+ (closed circles)
and Zfp36l1fl/fl CD79aCre/+ (open squares) mice at day 14 following primary immunization. Each symbol represents data from an individual mouse, and lines
represent means. Data are representative of at least two independent experiments (n = 5; the P value is for a Student’s t test). (J and K) An overlay of
representative flow cytometry plots showing surface expression of the integrin chains α4 (J) and β1 (K) on CD138+NIP+IgG1+ cells from the spleens of Zfp36l1fl/fl
CD79a+/+ (shaded histogram) and Zfp36l1fl/fl CD79aCre/+ (black line) mice analyzed 42 d after immunization.
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Figure S5. Dynamic regulation of the integrin chains α4, β1, and β7 and of CXCR4 on ASCs. (A) Schematic representation of the experimental setup for
comparison of NP-specific ASCs generated at different times during the immune response. (B–D) An overlay of representative flow cytometry plots showing
surface expression of CXCR4 (B) and of the integrin chains α4 (C) and β1 (D) on CD138+NIP+IgG1+ cells from the spleens of Zfp36l1fl/fl mice analyzed 14 d
(shaded histogram) and 42 d (black line) after immunization. (E) Schematic representation of the experimental setup for pulse labeling of ASCs with EdU and
detection of the newly arrived NP-specific ASCs to the BM. (F) Representative flow cytometry plots gated as in Fig. 1 D on CD138+NIP+IgG1+ cells and used for
identification of the EdU-low and EdU-high NP-specific ASCs in the BM at day 4 following reimmunization. For all flow cytometry plots, the numbers next to the
enclosed areas (gates) represent percentages of the cells falling into the gate, and the number in the bottom right corner shows the number of cells in the plot.
Arrows denote the hierarchical relationship between the cell populations. (G and H) ELISPOT analysis of the BM in Zfp36l1fl/fl CD79a+/+ (closed circles) and
Zfp36l1fl/fl CD79aCre/+ (open squares) mice for ASCs secreting anti-NP2 (high affinity) IgG1 antibody (G) and for ASCs secreting anti-NP23 (high and low affinity)
IgG1 antibody (H). The data in Fig. 1, B and C are presented as lines connecting the means of groups for each time point for each genotype.
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Provided online are two tables. Table S1 provides the details of differentially expressed genes between LPS-activated B cells from
ZFP36L1 cKO animals and from control animals. Table S2 lists the antibodies and other reagents used in this study.
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